Lynda Charters

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.

Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.

Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

During a presentation at the Bascom Palmer Eye Institute's Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition conference, David S. Boyer, MD, explained that the drug, which is being considered to treat diabetic retinopathy, renal disease, and age-related macular degeneration, is intended to be an alternative therapy to monthly chronically administered intravitreal injections of anti-VEGF drugs.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.

Glaucoma 360 is being held at the Grand Hyatt San Francisco at Union Square, and the meeting brings together celebration, innovation, and education in its efforts to eradicate glaucoma, with the Gala serving as the traditional kickoff of the event.

According to investigators at the University of Washington, Seattle, the COVID-19 pandemic has made measuring IOP challenging because of the potential to spread the virus.

According to investigators, the implant can provide a sustained infusion of drug to the retina

The future of this age-related condition is bright and in focus.

A new treatment option may increase basal tear production in patients.

Investigators are searching for a link between TIAs and changes in the back of the eye.

The new variant is described as a "subvariant" of the omicron variant and is closely related to omicron, though it has some different mutations.

Researchers collected data on COVID-19 symptoms via online surveys from in excess of 1 million 23andMe participants who self-reported their COVID-19 symptoms.

Investigators find that successful outcomes may depend on the awareness of red-flag symptoms and signs.

A study finds acceptable outcomes, vision, and microperimetry improvements at higher doses.

According to the companies, the trial will evaluate the safety, tolerability, and immune response of the vaccine that can be administered as a primary shot and a booster.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.

Canadian researchers have found that rapid antigen tests to detect the SARS-CoV-2 virus are associated with a very low rate of false positive results.

Physicians find that additional treatment is not required for many patients.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging

Informed guidelines are needed to diagnose and treat COVID-19 patients with neurologic manifestations, according to investigators.

The application of mitomycin C after corneal cross-linking does not prevent development of corneal haze after the procedure, but it does contribute to development of more corneal haze.

An evaluation conducted by the appropriate specialist is the most important factor in diagnosing and managing this patient population.

Striving to improve outcomes is important because of the negative effect of astigmatism on patients’ vision postoperatively.

The investigators believe that, based on their findings, the impact of COVID-19 on the autonomous nervous system warrants further prospective studies and assessment of pupillary function might be a useful test for determining autonomic dysfunction.

Investigators say study validates the importance of history-based donor screening while also demonstrating that postmortem PCR testing as a criterion for procurement and subsequent use of tissue isn’t necessary.